A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.Investors seeking a biotech stock with significant upside potential to add to their portfolio may want to consider Arcutis Biotherapeutics (ARQT 1.53%). The stock price is already up 112% in 2025, as I write, but there could be more to come in the next few years. Here's why.Arcutis has a bright futureThe company's primary pro ...